| 1.81 -0.19 (-9.5%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.43 |
1-year : | 2.68 |
| Resists | First : | 2.08 |
Second : | 2.29 |
| Pivot price | 2.1 |
|||
| Supports | First : | 1.73 |
Second : | 1.43 |
| MAs | MA(5) : | 2 |
MA(20) : | 2.08 |
| MA(100) : | 2.23 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.5 |
D(3) : | 33 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 67 | Low : | 1.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MENS ] has closed below the lower bollinger band by 21.7%. Bollinger Bands are 58.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 105 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.08 - 2.1 | 2.1 - 2.11 |
| Low: | 1.7 - 1.72 | 1.72 - 1.73 |
| Close: | 1.79 - 1.81 | 1.81 - 1.83 |
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Wed, 27 May 2026
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near Support - Put Flow Alert - The Legal Advocate
Mon, 11 May 2026
What Jyong Biotech (MENS) management focus reveals about priorities (Risk Aversion) 2026-05-11 - SMA Signal - The Legal Advocate
Fri, 27 Mar 2026
A plant-based prostate drug finished Phase III trials in the U.S. and Taiwan - Stock Titan
Mon, 29 Dec 2025
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Fri, 19 Dec 2025
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Fri, 19 Dec 2025
Jyong Biotech Responds to Share Price and Volume Movement - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 62.2 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 241 (K) |
| Shares Short P.Month | 133 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -30.17 |
| PEG Ratio | 0 |
| Price to Book value | -5.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -44.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|